Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
QTTB
STRONG BUYQ32 Bio Inc. · Healthcare · United States · $450M · Avg Vol: $28M/d
92
StockRankGet insider-trade alerts
Q
82
V
52
M
58
P/E (TTM)
5.4x
ROE
157.2%
D/E
0.3x
Dividend %
—
Loading 1Y...
PRICE (1Y)+19.3%
SMA 50SMA 200
Close
$15.15
RSI (14)
55.2
52W High
$23.57
From 52W High
0.6%
SCORE BREAKDOWN
Quality
82
ROIC
67.3%99.6
ROE
157.2%99.5
GP/Assets
62.3%92.3
Op. Margin
39.8%96.6
FCF/Assets
16.0%94.3
Piotroski
239.0
Int. Cover
28.1x73.7
D/E Ratio
0.29x41.8
Current Ratio
5.36x72.7
Value
52
P/E (TTM)
5.4x96.9
EV/EBITDA
10.1x67.9
P/FCF
45.6x27.9
P/B
4.8x28.9
P/S
8.4x30.4
Div Yield
—N/A
Momentum
58
52W High %
64%45.2
RS 6M
262%99.7
SMA 50/200
1.96x100.0
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-151%2.7
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$450M
P/E (Forward)
-10.7x
Gross Margin
71.6%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of QTTB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| QTTB | Q32 Bio Inc.(you) | $450M | 92 | STRONG BUY |
| PBYI | Puma Biotechnology, Inc. | $406M | 97 | STRONG BUY |
| CRMD | CorMedix Inc. | $617M | 98 | STRONG BUY |
| RIGL | Rigel Pharmaceuticals, Inc. | $680M | 98 | STRONG BUY |
| ZVRA | Zevra Therapeutics, Inc. | $563M | 81 | STRONG BUY |
| MDXG | MiMedx Group, Inc. | $626M | 75 | BUY |
| PLX | Protalix BioTherapeutics, Inc. | $191M | 99 | STRONG BUY |
| ABUS | Arbutus Biopharma Corporation | $865M | 81 | STRONG BUY |
| INVA | Innoviva, Inc. | $1.6B | 97 | STRONG BUY |
| NAGE | Niagen Bioscience, Inc. | $256M | 73 | BUY |
Peer medians: ROE -25.6% · P/E 27.9x · Gross margin 50.5%